Victrex (LON:VCT - Get Free Report) had its price target decreased by research analysts at JPMorgan Chase & Co. from GBX 940 ($12.77) to GBX 818 ($11.11) in a research note issued on Wednesday, Marketbeat.com reports. The brokerage currently has a "neutral" rating on the stock. JPMorgan Chase & Co.'s target price points to a potential upside of 12.36% from the stock's current price.
Victrex Trading Up 1.3%
Shares of VCT stock traded up GBX 9 ($0.12) on Wednesday, hitting GBX 728 ($9.89). The stock had a trading volume of 134,664 shares, compared to its average volume of 416,815. Victrex has a twelve month low of GBX 667.62 ($9.07) and a twelve month high of GBX 1,160 ($15.76). The firm has a market cap of £635.05 million, a P/E ratio of 20.68, a PEG ratio of 1.92 and a beta of 0.69. The company has a current ratio of 4.39, a quick ratio of 1.99 and a debt-to-equity ratio of 10.93. The company has a fifty day moving average price of GBX 795.78 and a two-hundred day moving average price of GBX 890.75.
Victrex (LON:VCT - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported GBX 22.60 ($0.31) earnings per share (EPS) for the quarter. Victrex had a net margin of 10.81% and a return on equity of 6.67%. As a group, analysts forecast that Victrex will post 73.1078905 earnings per share for the current fiscal year.
Insider Activity
In other Victrex news, insider David Thomas purchased 1,158 shares of the business's stock in a transaction on Tuesday, May 13th. The shares were purchased at an average cost of GBX 846 ($11.49) per share, with a total value of £9,796.68 ($13,308.90). Also, insider Dame Vivienne Cox purchased 2,747 shares of the business's stock in a transaction on Tuesday, July 8th. The shares were acquired at an average cost of GBX 721 ($9.79) per share, for a total transaction of £19,805.87 ($26,906.49). Insiders own 1.64% of the company's stock.
About Victrex
(
Get Free Report)
Victrex plc, through its subsidiaries, engages in the manufacture and sale of polymer solutions worldwide. The company operates through two segments, Sustainable Solutions and Medical. It develops PEEK and PAEK based polymer solutions, and semi-finished and finished parts. The company also provides specialist solutions for medical device manufacturers; sells thermoplastic polymers; sustainable solutions for energy and industrial, VAR, automotive, aerospace, and electronics markets; and engages in trading activities.
Featured Stories
Before you consider Victrex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Victrex wasn't on the list.
While Victrex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
